What is Amalgam Rx?
Amalgam Rx is a leader in integrating providers, life sciences, and digital solutions to transform care delivery within the chronic care ecosystem. For over 15 years, the company has focused on reimagining care delivery and driving lasting change. Partnering with prominent life sciences organizations, Amalgam Rx has developed an innovative platform designed for the rapid creation and scaling of digital health solutions across diverse business models. Their comprehensive methodology covers the entire product lifecycle, from research and development to commercialization. Amalgam Rx's solutions have already generated over 5 billion real-world evidence data points, utilized by patients and providers across three continents. The company's regulated and clinically validated technologies aim to enhance patient-provider connections, reduce payer costs, and generate sustained value for its partners.
How much funding has Amalgam Rx raised?
Amalgam Rx has raised a total of $52.3M across 3 funding rounds:
Series A
$17.4M
Other Financing Round
$27M
Private Equity
$7.9M
Series A (2023): $17.4M with participation from Novo Nordisk
Other Financing Round (2025): $27M led by Catalio Capital Management
Private Equity (2025): $7.9M, investors not publicly disclosed
Key Investors in Amalgam Rx
Novo Nordisk
Novo Nordisk is a global healthcare company with a long-standing commitment to combating serious chronic diseases. Their focus on innovative medicines and delivery systems, particularly in diabetes and rare blood and endocrine diseases, aligns with Amalgam Rx's mission to improve care delivery.
Catalio Capital Management
Catalio Capital Management is an investment firm specializing in breakthrough biomedical technology companies. Their expertise in healthcare investing across various markets suggests a strategic interest in Amalgam Rx's innovative platform and its potential for significant impact.
What's next for Amalgam Rx?
The substantial enterprise-level funding, including the recent strategic investment, positions Amalgam Rx for accelerated growth and market expansion. This capital infusion is expected to fuel further development of their digital health platform, enhance their R&D capabilities, and broaden their commercialization efforts. The company's focus on generating real-world evidence and its established partnerships with life sciences leaders suggest a strategic direction towards deeper integration within the healthcare value chain, potentially leading to new therapeutic area expansions or enhanced data analytics services. Amalgam Rx's trajectory indicates a strong commitment to leveraging technology for improved chronic disease management and value-based care.
See full Amalgam Rx company page
